Skip to main content

Table 2 Clinicopathological features and disease-free survival

From: Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy

Variables Univariate Multivariate
HR 95%CI p value HR 95%CI p-value
Age 0.67* 0.15–2.89 0.590 0.52* 0.10–2.62 0.426
Histology       
 NST vs others 0.57 0.25–1.28 0.172    
Residual tumour size in breast 5.30* 1.68–14.44 0.006 4.11* 1.01–14.86 0.048
Residual tumour in lymph node       
 Positive vs negative 2.98 1.62–5.49 < 0.001 2.54 1.29–5.09 0.007
Tumour grade       
 High vs low 1.27 0.69–2.31 0.444 1.33 0.63–2.75 0.443
Ki67 3.22* 0.91–10.67 0.070    
ER       
 Positive vs negative 0.91 0.49–1.67 0.758 0.66 0.26–1.62 0.360
PgR       
 Positive vs negative 1.04 0.57–1.88 0.905    
HER2       
 Positive vs negative 0.93 0.48–1.82 0.838 1.04 0.45–2.34 0.920
TIL 0.96* 0.32–2.50 0.938 1.22* 0.38–3.52 0.730
CD8 1.81* 0.30–8.60 0.497    
CD138 0.36* 0.06–1.63 0.201    
  1. ER oestrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, TIL tumour-infiltrating lymphocytes, NST no special type, HR hazard ratio, CI confidence interval
  2. *Range of the hazard ratio